Aromma Kapoor, MD
Nephrology · Hawthorne, NYNPI 1497941090
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (42.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Travere Therapeutics, Inc. accounts for 73.3% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $4,432 and has fallen 94.4% since, to $250 in 2025.
Across 34 payments — averaging $188.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$5K
- AstraZeneca$867
- Amgen$563
- Otsuka America Pharmaceutical, Inc.$123
- Calliditas Therapeutics US Inc.$119
- Aurinia Pharma U.S., Inc.$28
- plus $13 from 1 others
What the payments were for
- Consulting fees$2,70042%
- Travel & lodging$1,33121%
- Food & beverage$2,39437%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 15 | $4,711 |
| AstraZeneca(2 entities) | 8 | $867 |
| Amgen | 6 | $563 |
| Otsuka America Pharmaceutical, Inc. | 2 | $123 |
| Calliditas Therapeutics US Inc. | 1 | $119 |
| Aurinia Pharma U.S., Inc. | 1 | $28 |
| Vifor Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,425 in reported general payments places this provider in the 85th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VeltassaPatiromer Calcium Sorbitex | 15 | $4,075 |
| Eplerenone | 21 | $1,364 |
| Nifedipine ErNifedipine | 24 | $954 |
| Rosuvastatin Calcium | 14 | $240 |
| Amlodipine Besylate | 28 | $200 |
| Carvedilol | 32 | $169 |
| Spironolactone | 11 | $166 |
| Pantoprazole Sodium | 12 | $158 |
| Furosemide | 22 | $131 |
| Prednisone | 21 | $117 |
| Lisinopril | 22 | $88 |
| Ramipril | 12 | $83 |
| Losartan Potassium | 12 | $82 |
| Atorvastatin Calcium | 13 | $81 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Hawthorne
- Savneek ChughHawthorne$325K
- Payam ShakouriPoughkeepsie$930K
- Gerald AppelNew York$842K
- Richard ChanNew York$514K
- Bruce SpinowitzBronx$465K
- Steven CocaNew York$445K
- Joseph RoglieriTroy$425K
- Jai RadhakrishnanNew York$369K
- Gerard TepedinoManhasset$308K
- Frank CortazarAlbany$289K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.